Compare · BIIB vs FDMT
BIIB vs FDMT
Side-by-side comparison of Biogen Inc. (BIIB) and 4D Molecular Therapeutics Inc. (FDMT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and FDMT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $28.84B, about 63.9x FDMT ($451.7M).
- Over the past year, BIIB is up 46.2% and FDMT is up 77.2% - FDMT leads by 31.1 points.
- BIIB has been more active in the news (9 items in the past 4 weeks vs 2 for FDMT).
- BIIB has more recent analyst coverage (25 ratings vs 18 for FDMT).
- Company
- Biogen Inc.
- 4D Molecular Therapeutics Inc.
- Price
- $196.12+0.42%
- $8.53-1.45%
- Market cap
- $28.84B
- $451.7M
- 1M return
- +2.50%
- -14.41%
- 1Y return
- +46.17%
- +77.23%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 9
- 2
- Recent ratings
- 25
- 18
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
4D Molecular Therapeutics Inc.
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.
Latest BIIB
- Biogen upgraded by Needham with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.
- Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
- EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
- Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
- UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
- Stoke Therapeutics to Present at Upcoming Investor Conferences in June
- Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease
- BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations
- Evercore ISI resumed coverage on Biogen
Latest FDMT
- Officer Kirn David sold $19,258 worth of shares (1,922 units at $10.02) as part of a pre-agreed trading plan, decreasing direct ownership by 0.18% to 1,057,231 units (SEC Form 4)
- 4DMT to Participate in Upcoming Investor Conferences
- Amendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.
- 4DMT Announces New Employment Inducement Grants
- SEC Form EFFECT filed by 4D Molecular Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by 4D Molecular Therapeutics Inc.
- SEC Form S-3 filed by 4D Molecular Therapeutics Inc.
- SEC Form 10-Q filed by 4D Molecular Therapeutics Inc.
- 4D Molecular Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits